RxDoctor Payments Data

Newland Worley, MD

Otolaryngology · New Orleans, LANPI 1992760318

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Acclarent, Inc at 41.7% of the total. Reporting peaked in 2019 at $1,116 and has fallen 61.8% since, to $426 in 2025.

$3,719in general payments, 2019–2025

Across 171 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acclarent, Inc$2K
  • Optinose US, Inc.$498
  • Sanofi$296
  • GSK$218
  • Medical Device Business Services, Inc.$200
  • Regeneron Healthcare Solutions, Inc.$169
  • plus $785 from 15 others

What the payments were for

  • Travel & lodging$2005%
  • Food & beverage$3,48494%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,719 in reported general payments places this provider in the 75th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$103,524
Medicare patients
273
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$48,423
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth27$3,474
Cefdinir86$1,633
Fluticasone Propionate44$984
Ipratropium Bromide34$804
Ofloxacin37$723
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen40$597
Azelastine Hcl15$499
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$342
Prednisolone Acetate14$308
Omeprazole26$297
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$186
Prednisone141$184
Azithromycin57$179
Levothyroxine Sodium18$111

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →